Expected and Unexpected Outcomes of Probiotics and Metformin Interventions in Polyendocrine Metabolic Ovary Syndrome (PMOS, former PCOS): Findings from a Randomised Placebo-Controlled Trial

For millions of women worldwide, a complex condition known as Polyendocrine Metabolic Ovary Syndrome, formerly called Polycystic Ovary Syndrome, creates a tangled web of health challenges. This disorder disrupts the delicate balance of hormones that regulate reproduction and metabolism, often leading to irregular or absent menstrual cycles, elevated levels of male hormones that can cause unwanted hair growth, and difficulties with insulin, the body's key to processing sugar. Because the gut houses a vast community of bacteria that influences everything from digestion to hormone regulation, scientists have long wondered if helping this internal ecosystem might help heal the body. The idea is that by introducing beneficial bacteria, known as probiotics, one might restore order to a system that has gone awry, potentially offering a gentler alternative to existing medications that sometimes cause stomach upset or fail to work for everyone.

A team of researchers at the Medical University of Graz in Austria set out to test this idea with a rigorous six-month experiment. They recruited over one hundred women diagnosed with the syndrome and divided them into three groups to see what would happen. One group took a daily powder containing seven specific strains of beneficial bacteria along with a dose of vitamin D. Another group took a matching powder that looked and tasted the same but contained no active bacteria, serving as a placebo. The third group received the standard medication, metformin, which is widely used to improve how the body handles insulin. The goal was to see if the probiotic powder could lower free testosterone, a key hormone often too high in this condition, and to observe how the women's cycles, metabolism, and gut bacteria changed over time.

The results of the study offered a mix of surprising improvements and unexpected setbacks. The most significant positive finding was related to the menstrual cycle. Women who took the probiotic supplement saw their cycle lengths shorten dramatically, dropping by an average of forty days over the six months. This was a substantial improvement within the group, bringing many women closer to a regular monthly rhythm. The group taking metformin also saw their cycles shorten, though by a smaller amount, while the placebo group showed a smaller, non-significant reduction of about five days. Although the probiotic group's improvement was larger, the statistical difference between the probiotic and placebo groups was not significant, suggesting that while the intervention was associated with cycle shortening, the evidence for a distinct advantage over placebo in this specific metric requires further confirmation.

However, the study did not find the hoped-for reduction in testosterone levels. Despite the hopes that the probiotics would lower these male hormones, the levels remained largely unchanged in the probiotic group, just as they did in the placebo group. In fact, when comparing the groups, the women taking the probiotics actually saw a slight increase in androstenedione, a precursor to testosterone, compared to those taking the placebo or metformin. Furthermore, the study revealed a concerning trend in metabolic health. Contrary to the expectation that these interventions would improve how the body processes sugar, both the probiotic and metformin groups showed signs of worsening insulin resistance. Measures of insulin sensitivity declined, and triglyceride levels, a type of fat in the blood, rose in the probiotic group.

The researchers believe these mixed and sometimes negative results were heavily influenced by the timing of the study, which took place during the global COVID-19 pandemic. The six-month intervention period overlapped with strict lockdowns and significant lifestyle disruptions. The authors suggest that the stress, changes in diet, and reduced physical activity associated with the pandemic may have overwhelmed any potential benefits from the treatments. It is possible that the profound changes in daily life during this period acted as a powerful force that masked the effects of the probiotics and the medication, making it difficult to see a clear improvement in metabolic markers.

Despite the lack of metabolic improvement, the study provided valuable insights into the complexity of treating this syndrome. The probiotic supplement did successfully raise vitamin D levels in the women who took it, as the powder included this nutrient, but this did not translate into a broad metabolic cure. The gut bacteria composition, measured through advanced sequencing of stool samples, did not show the dramatic shifts in diversity or structure that some theories predicted. The study concludes that while probiotics may help regulate menstrual cycles, they are not a simple fix for the deeper metabolic and hormonal imbalances of the syndrome, especially when external factors like a global pandemic interfere with the body's ability to respond to treatment. The findings highlight that treating this condition requires looking at the whole picture, including the environment and lifestyle of the patient, rather than relying on a single supplement or pill.